Literature DB >> 19715481

Multiperc versus single perc with flexible instrumentation for staghorn calculi.

Arvind P Ganpule1, Shashikant Mishra, Mahesh R Desai.   

Abstract

Several techniques have been described for percutaneous access and stone removal. The method of choice depends on the available instrumentation, stone burden in given caliceal anatomy, and the surgeon's preference, depending on his or her level of training. The argument for multiple strategic tracts vs single-tract percutaneous nephrolithotomy (PCNL) with or without flexible instrumentation for complete clearance of the stones is ongoing. The "multiperc" or multiple tract approach offers clearance of stones without the added cost of sophisticated instrumentation; further, a surgeon who can achieve a primary tract can easily create secondary tracts. This does not require a learning curve to be overcome. The argument against the multiperc approach is a potential for increased bleeding, which has not been substantiated in any published series. The single-tract approach without need for flexible instrumentation, currently published, is for small burden and partial staghorn stone where multiple tracts are not really necessary. Use of single-tract PCNL with flexible instrumentation, such as ureteroscopy and nephroscopy, ideally needs a supracostal approach with its attendant morbidity. The success of this procedure depends on the collecting system anatomy. Few studies published to date report suboptimal stone clearance rates with the advantages of shorter hospital stay and less blood loss. The currently available literature is not sufficient because of mostly retrospective studies, fewer patient accrual, and paucity of staghorn cases. Proper prospective studies with head-on comparisons are needed to prove or disprove the advantages and disadvantages of either approach.

Entities:  

Mesh:

Year:  2009        PMID: 19715481     DOI: 10.1089/end.2009.1535

Source DB:  PubMed          Journal:  J Endourol        ISSN: 0892-7790            Impact factor:   2.942


  7 in total

1.  A patient of severe acute renal failure secondary to obstructive uropathy with an optimal outcome.

Authors:  Ranjit Chaudhary; Kulwant Singh; Rakesh Biswas; Rahul Chaudhary; Nidhi Jain
Journal:  BMJ Case Rep       Date:  2011-02-24

2.  Predictive factors of bleeding among pediatric patients undergoing percutaneous nephrolithotomy.

Authors:  Cagri Senocak; Ridvan Ozbek; Omer Faruk Bozkurt; Ali Unsal
Journal:  Urolithiasis       Date:  2017-07-12       Impact factor: 3.436

Review 3.  ECIRS (Endoscopic Combined Intrarenal Surgery) in the Galdakao-modified supine Valdivia position: a new life for percutaneous surgery?

Authors:  Cecilia Maria Cracco; Cesare Marco Scoffone
Journal:  World J Urol       Date:  2011-11-06       Impact factor: 4.226

4.  Treatment outcomes of retrograde intrarenal surgery for renal stones and predictive factors of stone-free.

Authors:  Soo Hyun Lim; Byong Chang Jeong; Seong Il Seo; Seong Soo Jeon; Deok Hyun Han
Journal:  Korean J Urol       Date:  2010-11-17

Review 5.  Recent finding and new technologies in nephrolitiasis: a review of the recent literature.

Authors:  Marco Rosa; Paolo Usai; Roberto Miano; Fernando J Kim; Enrico Finazzi Agrò; Pierluigi Bove; Salvatore Micali
Journal:  BMC Urol       Date:  2013-02-16       Impact factor: 2.264

6.  Single- versus Multiple-Tract Percutaneous Nephrolithotomy in the Surgical Management of Staghorn Stones or Complex Caliceal Calculi: A Systematic Review and Meta-analysis.

Authors:  Binbin Jiao; Zhenshan Ding; Zhenkai Luo; Shicong Lai; Xin Xu; Xing Chen; Guan Zhang
Journal:  Biomed Res Int       Date:  2020-12-17       Impact factor: 3.411

7.  External validation and evaluation of reliability and validity of the S-ReSC scoring system to predict stone-free status after percutaneous nephrolithotomy.

Authors:  Min Soo Choo; Chang Wook Jeong; Jae Hyun Jung; Seung Bae Lee; Hyeon Jeong; Hwancheol Son; Hyeon Hoe Kim; Seung-June Oh; Sung Yong Cho
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.